AAPL335.29+8.72 (+2.67%) ▲|ABBV256.43+1.43 (+0.56%) ▲|ABT101.74-1.62 (-1.57%) ▼|ACN180.17+2.26 (+1.27%) ▲|ADBE248.03-0.80 (-0.32%) ▼|AMAT463.70+9.69 (+2.13%) ▲|AMD517.08+13.48 (+2.68%) ▲|AMGN379.96-2.52 (-0.66%) ▼|AMT178.28+5.30 (+3.06%) ▲|AMZN255.90+4.01 (+1.59%) ▲|AVGO365.67+4.84 (+1.34%) ▲|AXP323.95+3.24 (+1.01%) ▲|BA209.03+4.23 (+2.07%) ▲|BAC62.77+0.21 (+0.34%) ▲|BKNG173.69-0.22 (-0.13%) ▼|BLK1,086.15+23.75 (+2.24%) ▲|BMY63.33-0.42 (-0.66%) ▼|BNY162.95+0.36 (+0.22%) ▲|BRK-B506.99-0.01 (0.00%) ▼|C138.49-0.01 (-0.01%) ▼|CAT821.43+16.43 (+2.04%) ▲|CL87.17-0.73 (-0.83%) ▼|CMCSA25.26+0.09 (+0.34%) ▲|COF207.32+0.21 (+0.10%) ▲|COP136.06-0.98 (-0.72%) ▼|COST903.31+0.93 (+0.10%) ▲|CRM248.33+5.33 (+2.19%) ▲|CSCO111.88+4.44 (+4.13%) ▲|CVS94.04-1.26 (-1.32%) ▼|CVX213.71+0.95 (+0.44%) ▲|DE685.84+7.90 (+1.17%) ▲|DHR200.47-0.07 (-0.03%) ▼|DIS106.92+1.10 (+1.04%) ▲|DUK119.81+0.41 (+0.34%) ▲|EMR150.99+2.62 (+1.77%) ▲|FDX311.14-0.66 (-0.21%) ▼|GD354.17-0.09 (-0.02%) ▼|GE323.91-0.25 (-0.08%) ▼|GEV951.57+27.66 (+2.99%) ▲|GILD143.66-1.15 (-0.79%) ▼|GM85.96-0.16 (-0.19%) ▼|GOOG338.74+8.35 (+2.53%) ▲|GOOGL341.70+9.10 (+2.74%) ▲|GS1,028.20+8.43 (+0.83%) ▲|HD309.33+3.64 (+1.19%) ▲|HON202.77+0.59 (+0.29%) ▲|IBM238.28+4.26 (+1.82%) ▲|INTC103.53+3.21 (+3.20%) ▲|INTU318.89+6.12 (+1.96%) ▲|ISRG367.64+7.18 (+1.99%) ▲|JNJ266.62+0.27 (+0.10%) ▲|JPM356.65+3.09 (+0.87%) ▲|KO88.00+0.17 (+0.19%) ▲|LIN464.70+3.08 (+0.67%) ▲|LLY1,120.39-2.62 (-0.23%) ▼|LMT524.42-5.71 (-1.08%) ▼|LOW197.49+0.90 (+0.46%) ▲|LRCX301.58+3.57 (+1.20%) ▲|MA567.37+2.00 (+0.35%) ▲|MCD252.95-0.10 (-0.04%) ▼|MDLZ62.27-0.20 (-0.32%) ▼|MDT90.38-1.24 (-1.35%) ▼|META653.34+8.96 (+1.39%) ▲|MMM163.88+1.02 (+0.62%) ▲|MO68.84+0.05 (+0.07%) ▲|MRK144.37-0.34 (-0.24%) ▼|MS213.45+0.79 (+0.37%) ▲|MSFT496.27+3.83 (+0.78%) ▲|MU978.44+1.03 (+0.11%) ▲|NEE82.37-0.07 (-0.08%) ▼|NFLX76.84+0.83 (+1.09%) ▲|NKE36.89+0.27 (+0.74%) ▲|NOW131.74+0.57 (+0.43%) ▲|NVDA219.84+1.48 (+0.68%) ▲|ORCL153.35+0.41 (+0.27%) ▲|PEP136.71+0.06 (+0.04%) ▲|PFE27.44-0.22 (-0.78%) ▼|PG144.00+1.03 (+0.72%) ▲|PLTR166.84+0.98 (+0.59%) ▲|PM192.68+2.95 (+1.55%) ▲|QCOM181.56+4.68 (+2.65%) ▲|RTX198.38+0.30 (+0.15%) ▲|SBUX99.78+0.56 (+0.56%) ▲|SCHW106.72-0.61 (-0.57%) ▼|SO88.21+0.46 (+0.52%) ▲|SPG205.01+0.27 (+0.13%) ▲|T25.91+0.35 (+1.35%) ▲|TMO609.66+6.51 (+1.08%) ▲|TMUS180.03+2.87 (+1.62%) ▲|TSLA364.96+1.40 (+0.38%) ▲|TXN267.37+8.55 (+3.30%) ▲|UBER72.19-0.37 (-0.51%) ▼|UNH385.23-3.05 (-0.79%) ▼|UNP287.61+1.83 (+0.64%) ▲|UPS100.00+0.03 (+0.03%) ▲|USB62.88+0.47 (+0.75%) ▲|V368.49+1.28 (+0.35%) ▲|VZ50.40+0.43 (+0.86%) ▲|WFC90.41+0.96 (+1.07%) ▲|WMT106.20+0.47 (+0.44%) ▲|XOM165.55+0.32 (+0.19%) ▲|AAPL335.29+8.72 (+2.67%) ▲|ABBV256.43+1.43 (+0.56%) ▲|ABT101.74-1.62 (-1.57%) ▼|ACN180.17+2.26 (+1.27%) ▲|ADBE248.03-0.80 (-0.32%) ▼|AMAT463.70+9.69 (+2.13%) ▲|AMD517.08+13.48 (+2.68%) ▲|AMGN379.96-2.52 (-0.66%) ▼|AMT178.28+5.30 (+3.06%) ▲|AMZN255.90+4.01 (+1.59%) ▲|AVGO365.67+4.84 (+1.34%) ▲|AXP323.95+3.24 (+1.01%) ▲|BA209.03+4.23 (+2.07%) ▲|BAC62.77+0.21 (+0.34%) ▲|BKNG173.69-0.22 (-0.13%) ▼|BLK1,086.15+23.75 (+2.24%) ▲|BMY63.33-0.42 (-0.66%) ▼|BNY162.95+0.36 (+0.22%) ▲|BRK-B506.99-0.01 (0.00%) ▼|C138.49-0.01 (-0.01%) ▼|CAT821.43+16.43 (+2.04%) ▲|CL87.17-0.73 (-0.83%) ▼|CMCSA25.26+0.09 (+0.34%) ▲|COF207.32+0.21 (+0.10%) ▲|COP136.06-0.98 (-0.72%) ▼|COST903.31+0.93 (+0.10%) ▲|CRM248.33+5.33 (+2.19%) ▲|CSCO111.88+4.44 (+4.13%) ▲|CVS94.04-1.26 (-1.32%) ▼|CVX213.71+0.95 (+0.44%) ▲|DE685.84+7.90 (+1.17%) ▲|DHR200.47-0.07 (-0.03%) ▼|DIS106.92+1.10 (+1.04%) ▲|DUK119.81+0.41 (+0.34%) ▲|EMR150.99+2.62 (+1.77%) ▲|FDX311.14-0.66 (-0.21%) ▼|GD354.17-0.09 (-0.02%) ▼|GE323.91-0.25 (-0.08%) ▼|GEV951.57+27.66 (+2.99%) ▲|GILD143.66-1.15 (-0.79%) ▼|GM85.96-0.16 (-0.19%) ▼|GOOG338.74+8.35 (+2.53%) ▲|GOOGL341.70+9.10 (+2.74%) ▲|GS1,028.20+8.43 (+0.83%) ▲|HD309.33+3.64 (+1.19%) ▲|HON202.77+0.59 (+0.29%) ▲|IBM238.28+4.26 (+1.82%) ▲|INTC103.53+3.21 (+3.20%) ▲|INTU318.89+6.12 (+1.96%) ▲|ISRG367.64+7.18 (+1.99%) ▲|JNJ266.62+0.27 (+0.10%) ▲|JPM356.65+3.09 (+0.87%) ▲|KO88.00+0.17 (+0.19%) ▲|LIN464.70+3.08 (+0.67%) ▲|LLY1,120.39-2.62 (-0.23%) ▼|LMT524.42-5.71 (-1.08%) ▼|LOW197.49+0.90 (+0.46%) ▲|LRCX301.58+3.57 (+1.20%) ▲|MA567.37+2.00 (+0.35%) ▲|MCD252.95-0.10 (-0.04%) ▼|MDLZ62.27-0.20 (-0.32%) ▼|MDT90.38-1.24 (-1.35%) ▼|META653.34+8.96 (+1.39%) ▲|MMM163.88+1.02 (+0.62%) ▲|MO68.84+0.05 (+0.07%) ▲|MRK144.37-0.34 (-0.24%) ▼|MS213.45+0.79 (+0.37%) ▲|MSFT496.27+3.83 (+0.78%) ▲|MU978.44+1.03 (+0.11%) ▲|NEE82.37-0.07 (-0.08%) ▼|NFLX76.84+0.83 (+1.09%) ▲|NKE36.89+0.27 (+0.74%) ▲|NOW131.74+0.57 (+0.43%) ▲|NVDA219.84+1.48 (+0.68%) ▲|ORCL153.35+0.41 (+0.27%) ▲|PEP136.71+0.06 (+0.04%) ▲|PFE27.44-0.22 (-0.78%) ▼|PG144.00+1.03 (+0.72%) ▲|PLTR166.84+0.98 (+0.59%) ▲|PM192.68+2.95 (+1.55%) ▲|QCOM181.56+4.68 (+2.65%) ▲|RTX198.38+0.30 (+0.15%) ▲|SBUX99.78+0.56 (+0.56%) ▲|SCHW106.72-0.61 (-0.57%) ▼|SO88.21+0.46 (+0.52%) ▲|SPG205.01+0.27 (+0.13%) ▲|T25.91+0.35 (+1.35%) ▲|TMO609.66+6.51 (+1.08%) ▲|TMUS180.03+2.87 (+1.62%) ▲|TSLA364.96+1.40 (+0.38%) ▲|TXN267.37+8.55 (+3.30%) ▲|UBER72.19-0.37 (-0.51%) ▼|UNH385.23-3.05 (-0.79%) ▼|UNP287.61+1.83 (+0.64%) ▲|UPS100.00+0.03 (+0.03%) ▲|USB62.88+0.47 (+0.75%) ▲|V368.49+1.28 (+0.35%) ▲|VZ50.40+0.43 (+0.86%) ▲|WFC90.41+0.96 (+1.07%) ▲|WMT106.20+0.47 (+0.44%) ▲|XOM165.55+0.32 (+0.19%) ▲|
23.1 C
New York
Friday, September 11, 2026

Tag: study

newssourceFORcompanyinformationcontent1releasesmarket

CCTV-4’s Special Central Asia Season A Celebration of Regional Exchange and Cooperation

BEIJING, June 16, 2025 /PRNewswire/ -- To coincide with the 2nd China-Central Asia Summit, being held in Astana, the capital of Kazakhstan, from June...

From Fast Meals to Eco Feels: How Singapore’s Dining Habits Are Driving Sustainable Packaging Innovation

JAKARTA, Indonesia, June 17, 2025 /PRNewswire/ -- Dining out has become a way of life for Singaporeans. According to a recent study by Euromonitor, the...

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Red Cat, Reckitt, UroGen and Fortrea and Encourages Investors...

NEW YORK, June 16, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Reckitt Benckiser Group plc (OTC:RBGLY), UroGen Pharma Ltd. (NASDAQ:URGN), Red Cat Holdings, Inc. (NASDAQ: RCAT) and Fortrea Holdings Inc. (NASDAQ:FTRE). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Vestis, PepGen, Tempus, and Rocket and Encourages Investors to...

NEW YORK, June 16, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Vestis Corporation (NYSE:VSTS), PepGen, Inc. (NASDAQ: PEPG), Tempus AI, Inc. (NASDAQ: TEM), and Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.

Lumina Gold Announces Securityholder Approval of Acquisition by CMOC

VANCOUVER, BC, June 16, 2025 /PRNewswire/ - Lumina Gold Corp. (TSXV: LUM) (OTCQB: LMGDF) (the "Company" or "Lumina") is pleased to announce that, the holders ("Shareholders") of...

U.S. Food and Drug Administration Approves CSL’s ANDEMBRY® (garadacimab-gxii), the Only Prophylactic Hereditary Angioedema (HAE) Treatment Targeting Factor XIIa with Once-Monthly Dosing for All...

ANDEMBRY inhibits the top of the HAE cascade by targeting factor XIIa and provides sustained protection from attacksOnce-monthly dosing reduced HAE attacks by a...

PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results

PETACH TIKVA, Israel, June 17, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that following its recently announced successful SHIELD II phase 3 topline results, it has secured additional funding through the exercise of warrants with aggregate gross proceeds of $26.7 million. The Company anticipates that with this additional funding, PolyPid’s runway would be extended beyond anticipated FDA approval of D-PLEX₁₀₀.

ANAVEX SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Anavex Life Sciences Corp. (NASDAQ: AVXL) and Encourages Long-Term Investors to Contact the Firm

PHILADELPHIA, June 16, 2025 (GLOBE NEWSWIRE) -- The law firm of Kaskela Law LLC announces that it is investigating potential breach of fiduciary duty claims concerning Anavex Life Sciences Corp. (NASDAQ: AVXL) (“Anavex”) on behalf of the company’s long-term shareholders. 

Chronic Lower Back Pain Market to Expand Significantly During the Forecast Period (2025-2034) with Game-Changing Therapies | DelveInsight

The overall chronic lower back pain market is expected to boost with the expected launch of emerging therapies such as SP-102 (Scilex Holding), Rexlemestrocel-L...

New Found Gold Expands Queensway Gold Project 2025 Work Program

VANCOUVER, BC, June 16, 2025 /PRNewswire/ - New Found Gold Corp. ("New Found Gold" or the "Company") (TSX-V: NFG) (NYSE-A: NFGC) is pleased to...

High Tide Reports Second Fiscal Quarter 2025 Financial Results

 The Company Generates $4.9 Million in Free Cash Flow Daily Same Store Sales Across the Canna Cabana Network Increased by 6.2% Year Over Year The Company...

MENA’s Electric Vehicle Market Expected to Reach $14.5 Billion by the end of 2029

"In-Depth Analysis of the MENA Electric Vehicle Market: Forecasting Trends, Technological Advances, and Regulatory Policies from 2024 to 2029" BOSTON, June 16, 2025 /PRNewswire/ --...

CCTV-4’s Special Central Asia Season

A Celebration of Regional Exchange and Cooperation BEIJING, June 16, 2025 /PRNewswire/ -- To coincide with the 2nd China-Central Asia Summit, being held in Astana,...

En termes d’efficacité, une comparaison indirecte des traitements suggère un avantage significatif d’IMBRUVICA® (ibrutinib) associé au vénétoclax par rapport à l’acalabrutinib associé au vénétoclax...

Les résultats d’études croisées de l’association ibrutinib et vénétoclax en première intention montrent un bénéfice clinique significatif pour une durée fixe, ainsi qu’une probabilité accrue de maladie résiduelle minimale indétectable et de survie sans progression par rapport à l’association acalabrutinib et vénétoclax1

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsStudy

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers